During the last decade, the therapeutic management of hepatitis C virus (HCV) infection has changed dramatically. Due to the recent approval of several directly acting antiviral agents (DAAs) such as sofosbuvir, daclatasvir, or ledipasvir, HCV eradication is possible in the vast majority of HCV infected individuals by DAA combinations with or without pegylated interferon-α. This review summarized these exciting developments with a focus on current recommendations for the treatment of chronic hepatitis C.
AbstractDuring the last decade, the therapeutic management of hepatitis C virus (HCV) infection has changed dramatically. Due to the recent approval of several directly acting antiviral agents (DAAs) such as sofosbuvir, daclatasvir, or ledipasvir, HCV eradication is possible in the vast majority of HCV infected individuals by DAA combinations with or without pegylated interferon-α. This review summarized these exciting developments with a focus on current recommendations for the treatment of chronic hepatitis C.